[1] Tolusso B, Fabris M, Gremese E, et al. Platelet GPⅡb/Ⅲa(PIA 1/2)polymorphism in SLE: clinical and laboratory association [J]. Ann Rheum Dis, 2003, 62(8): 781-2. [2] 苏尚焙.系统性红斑狼疮474例临床分析[J].临床皮肤科杂志,1996,25(2):80-1.SuSP. Clinical analysis of 34 case of systemic lupus erythematosus [J]. J Clin Dermatol, 1996, 25(2): 80-1. [3] 林文杰,陈韧,许敬才,等.15例系统性红斑狼疮长期误诊为特发性血小板减少性紫癜的临床分析[J].实用医学杂志,1997,13(9):629. [4] 赵辨.临床皮肤性病学[M].第3版,南京:江苏科学技术出版社,2001.661. [5] 秦秀娟,郭岿.补体与血沉在系统性红斑狼疮病情转归中的意义[J].现代中西医结合杂志,2001,10(4):352. [6] 毛达勇,崔礼敬,闫文强,等.血小板四参数正常参考范围的研究[J].郧阳医学院学报,1996,15(2):84.Mao DY, Cui LJ, Yan WQ, et al. The study of four parameters reference value of PLT[J]. J Yunyang Med Coll, 1996, 15(2): 84. [7] Koltai M, Hosford D, Guinot P, et al. Platelet activating factor (PAF).A review of its efects, antagonists possible future clinical applications (Part Ⅰ)[J]. Drugs, 1991, 42(1): 9-29. [8] Ruiz-Ortega M, Bustos C, Plaza J J, et al. Overexpression of extracellular matrix proteins in renal tubulointerstitial cells by plateletactivating-factor stimulation[J]. Nephrol Dial Transplant, 1998, 13(4): 886-92. [9] 陈慰峰.医学免疫学[M].第4版,北京:人民卫生出版社,2004.202. |